MyoKardia (MyoKardia) Repurchase of Stock : $0.00 Mil (TTM As of Sep. 2020)

View and export this data going back to 2015. Start your Free Trial

What is MyoKardia Repurchase of Stock?

MyoKardia's Repurchase of Stock for the three months ended in Sep. 2020 was $0.00 Mil.

MyoKardia's Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2020 was $0.00 Mil.

MyoKardia Repurchase of Stock Historical Data

The historical data trend for MyoKardia's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyoKardia Repurchase of Stock Chart

MyoKardia Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Repurchase of Stock

Get a 7-Day Free Trial

MyoKardia Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Repurchase of Stock	Get a 7-Day Free Trial															-	-	-	-	-

MyoKardia Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

MyoKardia Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of MyoKardia's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

MyoKardia (MyoKardia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyoKardia Inc (NAS:MYOK) » Definitions » Repurchase of Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Sierra Point Parkway, Brisbane, CA, USA, 94005

Website

https://www.myokardia.com

MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.

Executives

Anastasios Gianakakos	director, officer: President and CEO	333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Denelle J Waynick	officer: General Counsel	C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary B Cranston	director	C/O VISA INC., P.O. BOX 8999, SAN FRANCISCO CA 94128-8999
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
David P Meeker	director	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Wendy L Yarno	director
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Kimberly J Popovits	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jake Bauer	officer: Chief Business Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Taylor C. Harris	officer: Chief Financial Officer	6035 STONERIDGE DRIVE, PLEASANTON CA 94588
William Fairey	officer: See Remarks	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Cynthia J Ladd	officer: General Counsel	C/O AGY THERAPEUTICS INC, 290 UTAH AVE, SOUTH SAN FRANCISCO CA 94080
Robert Scott Mcdowell	officer: Chief Scientific Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
June Lee	officer: EVP, Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017